FDA Approves Injectable Ocrevus Zunovo for Relapsing, Progressive MS

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 26, 2024.

By Lori Solomon HealthDay Reporter

THURSDAY, Sept. 26, 2024 -- The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis (MS).

The injection is administered by a health care professional. Patients are given premedications at least 30 minutes prior to each dose and then monitored by their health care provider for at least 60 minutes after the injection. For subsequent doses, patients will be monitored for at least 15 minutes after the injection.

The approval was based on results from the phase 3 OCARINA II trial, which showed no clinically significant difference in the levels of Ocrevus in the blood when administered subcutaneously versus intravenously. The safety and efficacy profile was consistent with the intravenous formulation, with Ocrevus demonstrating suppression of relapse activity (97 percent) and magnetic resonance imaging lesions (97 percent) through 48 weeks. For patient-reported outcomes, more than 92 percent of participants reported being satisfied or very satisfied with the subcutaneous administration. The most common adverse events seen with Ocrevus were injection reactions, with 49 percent of participants experiencing a reaction after the first injection. All reactions were either mild or moderate, with none leading to treatment withdrawal.

"It's crucial to acknowledge each experience with MS is as unique as the individual navigating it, so providing choices to address each person's needs is essential," Natalie Blake, executive director of the MS Foundation, said in a statement. "We are pleased that with a new method of delivery, there is now an additional option for those who need flexibility in the route of administration or treatment time."

Approval of Ocrevus Zunovo was granted to Genentech.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-09-27 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords